# SYN1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The SYN1 gene, located on the X chromosome (Xp11.23), encodes synapsin I, a crucial presynaptic phosphoprotein regulating synaptic vesicle (SV) trafficking, clustering, and the reserve pool. Its neuron-specific expression is tightly controlled by Sp1 and REST transcription factors, with epigenetic regulation by DNA methylation.
- Pathogenic variants in SYN1, primarily leading to loss-of-function, cause a spectrum of X-linked neurodevelopmental disorders including epilepsy (notably reflex bathing epilepsy), autism spectrum disorder (ASD), and intellectual disability (ID). Males are typically more severely affected due to X-linked inheritance.
- Synapsin I's function is modulated by phosphorylation at specific sites (Ser9 by PKA/CaMKI, Ser566/603 by CaMKII), which releases SVs from the actin cytoskeleton, facilitating neurotransmitter release. Dephosphorylation by calcineurin restores SV tethering, regulating synaptic plasticity.
- The SYN1 promoter is a widely utilized tool in neuroscience and gene therapy for achieving neuron-specific transgene expression in viral vectors (e.g., AAV, adenovirus) and transgenic models, enabling targeted manipulation of neuronal function.
- Therapeutic strategies for SYN1-related disorders are currently symptomatic, focusing on antiseizure medications (ASMs) with variable efficacy and management of comorbidities. Investigational approaches include gene replacement therapy and modulation of synaptic plasticity pathways.

---

## Executive Summary & Key Metadata

The SYN1 gene encodes synapsin I (SynI), a neuronal phosphoprotein that is a principal component of the presynaptic terminal. Synapsin I is a member of the synapsin family (SYN1, SYN2, SYN3), which are encoded by distinct genes and are among the most abundant proteins on synaptic vesicles (SVs). The protein is fundamentally involved in the regulation of synaptic vesicle trafficking, clustering, and the maintenance of the reserve pool of vesicles at presynaptic boutons. Beyond its canonical role in neurotransmitter release, SYN1 is implicated in neuronal development, axonogenesis, and synaptogenesis. Pathogenic variants in SYN1 are a well-established cause of X-linked neurodevelopmental disorders, with a spectrum that includes reflex epilepsy (particularly bathing epilepsy), autism spectrum disorder (ASD), intellectual disability (ID), and behavioral abnormalities. The gene is also a critical tool in molecular neuroscience, as its promoter is widely used to drive neuron-specific transgene expression in viral vectors and transgenic models. This reference manual provides a comprehensive, biophysically detailed overview of the SYN1 gene, from its genomic architecture and protein domain structure to its clinical significance and pharmacogenomic relevance.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | SYN1 |
| **UniProt Accession** | P17600 |
| **Representative PDB ID** | True (Multiple structures available for domains) |
| **Chromosomal Locus** | Xp11.23 |
| **Primary Molecular Function** | Synaptic vesicle phosphoprotein; regulation of vesicle trafficking, clustering, and neurotransmitter release |
| **Disease & Pathology Associations** | X-linked epilepsy (reflex bathing epilepsy), Autism Spectrum Disorder (ASD), X-linked Intellectual Disability (XLID), Neurodevelopmental Disorders (NDDs) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SYN1 gene is located on the short arm of the X chromosome at cytogenetic band Xp11.23 [1]. This region is a well-characterized hotspot for neurogenetic disorders, containing a high density of genes implicated in intellectual disability and epilepsy [1, 2]. The gene is oriented on the minus strand of the X chromosome. The genomic span of SYN1 is approximately 43 kilobases (kb), encompassing 13 exons that are alternatively spliced to generate multiple isoforms [3, 4].

The X-linked inheritance pattern of SYN1-related disorders is a critical clinical consideration. Males, who are hemizygous for the X chromosome, are typically more severely affected by pathogenic SYN1 variants. Females, who have two X chromosomes, may exhibit variable expressivity due to random X-chromosome inactivation (lyonization), which can lead to a mosaic expression of the wild-type and mutant alleles [4, 5]. This phenomenon explains the clinical heterogeneity observed in female carriers, who may range from asymptomatic to presenting with mild seizures or learning difficulties.

### 1.2 Promoter Architecture and Transcriptional Regulation

The 5' flanking region of SYN1 lacks a canonical TATA box but is characterized by a high GC content, a feature common to housekeeping and neuronal genes. The core promoter contains multiple binding sites for the transcription factor Specificity Protein 1 (Sp1) [6]. Sp1 is a ubiquitous transcription factor that binds GC-rich motifs and is essential for the basal and regulated transcription of SYN1. Paonessa et al. (2012) demonstrated that Sp1 directly binds to the SYN1 promoter and activates its transcription, establishing Sp1 as a novel and critical regulator of SYN1 expression [6].

The activity of Sp1 on the SYN1 promoter is modulated by the RE1-silencing transcription factor (REST), also known as Neuron-Restrictive Silencer Factor (NRSF). REST is a master negative regulator of neuronal gene expression in non-neuronal tissues. It binds to a conserved RE1 motif within the SYN1 promoter region, recruiting corepressor complexes that include histone deacetylases (HDACs) and the REST corepressor 1 (RCOR1) [6, 7]. The interplay between the activating Sp1 and the repressive REST is a key determinant of the neuron-specific expression of SYN1. In non-neuronal cells, REST is active and suppresses SYN1 transcription; in mature neurons, REST levels are low, allowing Sp1 to drive high-level expression [6].

Furthermore, the SYN1 promoter is subject to epigenetic regulation via DNA methylation. The promoter region contains a CpG island, and hypermethylation of these CpG dinucleotides is associated with transcriptional silencing [6]. Paonessa et al. (2012) showed that 5'-cytosine-phosphoguanine (CpG) methylation within the SYN1 promoter inhibits Sp1 binding, providing a direct mechanistic link between DNA methylation and reduced SYN1 expression [6]. This epigenetic control is relevant to various neurological and psychiatric conditions where SYN1 dysregulation has been observed [8, 9, 10, 11].

### 1.3 Enhancer Elements and 3D Chromatin Architecture

While the core promoter is well-characterized, the full complement of cis-regulatory elements for SYN1 is still under investigation. The high gene density of the Xp11.23 region suggests that long-range chromatin interactions and topologically associating domains (TADs) play a role in the precise spatiotemporal control of SYN1 expression [1, 2]. The promoter also contains a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) responsive region, which is not endogenous but is frequently used in expression vectors to enhance transgene mRNA stability and translation [12]. The SYN1 promoter is highly conserved across mammals, as demonstrated by the functional characterization of the porcine orthologue, which showed a high degree of sequence conservation of promoter elements, including the Sp1 and REST binding sites [13].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the 13 exons of SYN1 gives rise to two major isoforms, Synapsin Ia (SynIa) and Synapsin Ib (SynIb), which differ in their C-terminal regions. The longer isoform, SynIa, includes an additional C-terminal extension encoded by a distal exon, which contains a proline-rich domain and an additional phosphorylation site. Both isoforms share the N-terminal domains (A, B, and C) but diverge in the C-terminal domains (D and E). The differential expression of these isoforms is developmentally regulated and cell-type specific, contributing to the functional diversity of synapsin I in different neuronal populations. The specific functions of the C-terminal domains are discussed in Section 2.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human synapsin I protein is composed of 705 amino acids (for the SynIa isoform) with a molecular weight of approximately 74 kDa. The protein is organized into five distinct domains, designated A through E from the N-terminus to the C-terminus. Each domain has specific structural and functional properties.

- **Domain A (N-terminal, ~30 amino acids):** This short domain is highly conserved across all synapsins. It contains a single phosphorylation site for cAMP-dependent protein kinase (PKA) and Ca2+/calmodulin-dependent protein kinase I (CaMKI) at Serine 9. This phosphorylation is critical for the dissociation of synapsin I from synaptic vesicles during neuronal activity.
- **Domain B (~30 amino acids):** A short, proline-rich linker domain connecting domains A and C. It contains phosphorylation sites for Ca2+/calmodulin-dependent protein kinase II (CaMKII) at Serine 566 and Serine 603 (numbering for human SynIa). Phosphorylation by CaMKII at these sites is a key regulatory event for the release of synapsin from vesicles and the mobilization of the reserve pool.
- **Domain C (~300 amino acids):** This is the central, highly conserved "synapsin core" domain. It is responsible for the ATP-binding and dimerization properties of the protein. The domain C structure is composed of a central beta-sheet flanked by alpha-helices, forming a stable globular structure. It mediates the binding of synapsin I to synaptic vesicles, likely through interactions with phospholipids and other vesicle-associated proteins. This domain also binds to actin filaments, contributing to the cytoskeletal tethering of vesicles.
- **Domain D (~100 amino acids):** A variable domain that is subject to alternative splicing. It is rich in proline, glycine, and serine residues, and contains the CaMKII phosphorylation sites. This domain is thought to be flexible and to mediate protein-protein interactions.
- **Domain E (C-terminal, ~200 amino acids):** This domain is unique to synapsin I and is not present in synapsins II and III. It is a proline-rich domain that binds to SH3 (Src Homology 3) domain-containing proteins, such as Grb2 and amphiphysin. This domain is also involved in the interaction with actin and in the regulation of synapsin's own phosphorylation state.

### 2.2 Quaternary Structure and Ligand Binding

Synapsin I exists as a dimer in solution, a property mediated by the domain C. Dimerization is thought to be important for its ability to cross-link synaptic vesicles and actin filaments, thereby clustering vesicles within the reserve pool. The ATP-binding site is located within domain C, and ATP hydrolysis is not required for vesicle binding but may regulate the conformational state of the protein.

The interaction of synapsin I with synaptic vesicles is complex and involves both protein-lipid and protein-protein interactions. The N-terminal domains (A-C) are primarily responsible for binding to the vesicle membrane, likely through electrostatic interactions with negatively charged phospholipids. The C-terminal domains (D-E) are more involved in protein-protein interactions, linking synapsin to the actin cytoskeleton and to other regulatory proteins.

### 2.3 Interactive 3D Visualization

To explore the three-dimensional architecture of the synapsin I protein, including its domain organization and key phosphorylation sites, an interactive 3D visualizer is available. This tool allows for the manipulation of the protein structure, highlighting the spatial arrangement of functional domains and the location of clinically relevant mutations.

[Interactive 3D Protein Visualizer: Load SYN1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P17600)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Synaptic Vesicle Cycle and Neurotransmitter Release

The primary function of synapsin I is to regulate the trafficking and availability of synaptic vesicles at the presynaptic terminal. In resting neurons, synapsin I tethers SVs to the actin cytoskeleton, maintaining a large reserve pool of vesicles that are not immediately releasable. Upon neuronal depolarization, calcium influx triggers a signaling cascade that leads to the phosphorylation of synapsin I.

The key phosphorylation events are:
1.  **Phosphorylation by PKA/CaMKI at Serine 9 (Domain A):** This phosphorylation is permissive and is thought to prime the protein for subsequent phosphorylation events.
2.  **Phosphorylation by CaMKII at Serines 566 and 603 (Domain B/D):** This is the primary trigger for the dissociation of synapsin I from SVs and the actin cytoskeleton. This phosphorylation reduces the affinity of synapsin I for both SVs and actin, freeing the vesicles from the reserve pool and allowing them to translocate to the active zone for exocytosis [14].

This process is reversible; upon dephosphorylation by calcineurin (protein phosphatase 2B), synapsin I re-associates with SVs, promoting their re-clustering and the replenishment of the reserve pool [15, 16]. This cycle of phosphorylation and dephosphorylation is a fundamental mechanism for the short-term regulation of neurotransmitter release and synaptic plasticity.

### 3.2 Differential Regulation of Excitatory and Inhibitory Synapses

The role of synapsin I is not uniform across all synapse types. Studies using synapsin I knockout (KO) mice have revealed a differential impact on excitatory (glutamatergic) and inhibitory (GABAergic) synapses. At inhibitory synapses, the absence of synapsin I leads to a significant reduction in the size of the readily releasable pool (RRP) of synaptic vesicles, resulting in a decreased probability of release [14]. In contrast, at excitatory synapses, the primary effect is a reduction in the reserve pool, leading to a more pronounced synaptic depression during high-frequency stimulation [1].

This differential regulation is critical for maintaining the excitation/inhibition (E/I) balance in neuronal networks. The loss of synapsin I shifts the balance towards hyperexcitability, as the reduction in inhibitory drive is more profound than the reduction in excitatory drive. This network-level hyperexcitability is the cellular basis for the epileptic phenotype observed in SYN1-related disorders [1, 2].

### 3.3 Role in Neuronal Development and Synaptogenesis

Beyond its role in mature synaptic transmission, synapsin I is critical for neuronal development. It is expressed early in development and is involved in axon outgrowth, pathfinding, and the formation of new synapses [3, 4]. Synapsin I promotes the elongation of axons and the formation of growth cones, and it is essential for the proper clustering of SVs at nascent synapses. Loss-of-function mutations in SYN1 impair these developmental processes, contributing to the neurodevelopmental phenotypes (ID, ASD) seen in patients [3, 4].

### 3.4 Protein-Protein Interaction Networks

Synapsin I interacts with a wide array of proteins, forming a complex regulatory network. Key interactors include:

- **Cytoskeletal proteins:** Actin and tubulin. These interactions are essential for vesicle tethering and transport.
- **SH3-domain proteins:** Grb2, amphiphysin, and endophilin. These interactions link synapsin to signaling pathways and endocytic machinery.
- **Signaling proteins:** Calcineurin, CaMKII, PKA, and cyclin-dependent kinase 5 (Cdk5). These regulate the phosphorylation state of synapsin.
- **Other synaptic proteins:** PRICKLE1, a protein associated with ASD and epilepsy, directly interacts with synapsin I. This interaction is thought to be important for the regulation of synaptic vesicle cycling, and mutations in PRICKLE1 that disrupt this interaction contribute to ASD pathogenesis [5].
- **Dystrophin-Glycoprotein Complex (DGC):** In Drosophila, the Dg-Dys-Syn1 signaling pathway has been shown to regulate the microRNA profile, indicating a role for synapsin in broader gene expression regulation [6].

### 3.5 Signaling Pathways and Transcriptional Regulation

The expression of SYN1 itself is regulated by neurotrophic factors and neuronal activity. The BDNF-TrkB signaling pathway, which is crucial for synaptic plasticity and antidepressant response, influences the expression of SYN1 [7]. Furthermore, the transcription factor CREB (cAMP response element-binding protein), a downstream target of many neuronal signaling cascades, is involved in the regulation of SYN1 expression [8]. The GPR3 receptor, a constitutively active Gs-coupled receptor, promotes CREB-dependent neuronal differentiation, which is associated with increased SYN1 expression [8]. This places SYN1 within a broader network of genes that mediate neuroplasticity and the response to environmental stimuli.

```mermaid
sequenceDiagram
    participant Pre as "Presynaptic Terminal"
    participant SV as "Synaptic Vesicle (SV)"
    participant Syn as "Synapsin I (SYN1)"
    participant Ca as "Voltage-Gated Ca2+ Channel"
    participant Kin as "Kinases (PKA, CaMKII)"
    participant Act as "Actin Cytoskeleton"
    Note over Pre, Act: Resting State
    Syn->>SV: Tethers SV (via Domains A-C)
    Syn->>Act: Binds Actin (via Domains D-E)
    Note over SV, Act: SV held in Reserve Pool

    Note over Pre, Ca: Action Potential Arrival
    Ca->>Pre: Depolarization & Ca2+ Influx
    Ca->>Kin: Activates PKA & CaMKII
    Kin->>Syn: Phosphorylates Syn (Ser9, Ser566/603)
    Syn-->>SV: Dissociates from SV
    Syn-->>Act: Dissociates from Actin
    SV->>Pre: Mobilizes to Active Zone
    Note over Pre: Neurotransmitter Release

    Note over Pre, Act: Post-Stimulation
    Phosphatase->>Syn: Dephosphorylates Syn
    Syn->>SV: Re-binds SV
    Syn->>Act: Re-binds Actin
    Note over SV, Act: SV Re-clusters into Reserve Pool
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Spectrum of SYN1 Pathogenic Variants

Pathogenic variants in SYN1 are a well-established cause of a spectrum of X-linked neurodevelopmental disorders. The clinical presentation is highly variable, even within the same family, and includes epilepsy, intellectual disability, autism spectrum disorder, and behavioral abnormalities [3, 4, 5]. The most distinctive clinical feature associated with SYN1 mutations is reflex epilepsy, particularly seizures triggered by bathing or contact with water [3, 9, 10, 11].

The types of mutations identified in SYN1 include missense, nonsense, and frameshift variants, all of which typically result in a loss-of-function (LoF) mechanism [3]. The loss of a single functional copy of SYN1 in males is sufficient to cause disease, indicating haploinsufficiency as the primary disease mechanism.

### 4.2 Specific Pathogenic Mutations and Their Mechanisms

Several specific mutations have been functionally characterized, providing insight into the molecular pathogenesis of SYN1-related disorders.

- **Q555X (c.1663C>T):** This is a recurrent nonsense mutation that introduces a premature stop codon in the domain D region. This mutation is a well-established cause of X-linked epilepsy with reflex bathing seizures [2, 12]. The truncated protein lacks the C-terminal domain E and part of domain D. Functional studies have shown that the Q555X mutation leads to a dominant-negative effect, where the mutant protein interferes with the function of the wild-type protein. This mutation triggers imbalances in release dynamics and short-term plasticity, leading to a more severe phenotype than a simple loss of one allele [2]. Structural imaging studies in patients with this mutation have revealed alterations in cortical gray matter microstructure, particularly in regions involved in sensorimotor integration, which may explain the reflex nature of the seizures [12].
- **W356X (c.1068G>A):** This nonsense mutation in domain C is another cause of X-linked epilepsy. The W356X mutation triggers nonsense-mediated mRNA decay (NMD), leading to a complete loss of the protein [13]. This is a classic LoF mutation, and the phenotype is primarily due to haploinsufficiency.
- **Missense Mutations:** Several missense mutations have been identified, including a novel missense mutation associated with non-syndromic X-linked intellectual disability [14]. This mutation was shown to affect the synaptic vesicle life cycle, clustering, and mobility, without causing overt epilepsy, highlighting the phenotypic heterogeneity associated with SYN1 mutations [14]. Other missense mutations have been identified in patients with ASD and partial epilepsy, and functional studies have confirmed that these mutations impair synaptic function [3].

### 4.3 Clinical Phenotypes and Genotype-Phenotype Correlations

The clinical spectrum of SYN1-related disorders is broad, and genotype-phenotype correlations are still emerging. However, some general patterns are observed:

- **Epilepsy:** The most common phenotype, present in the majority of affected males. Seizures are often focal, with reflex bathing seizures being a distinctive feature [3, 10, 11]. The age of onset is typically in early childhood.
- **Intellectual Disability (ID):** Ranges from mild to severe. Non-syndromic X-linked ID has been reported in families with SYN1 mutations [14, 15].
- **Autism Spectrum Disorder (ASD):** A significant proportion of patients with SYN1 mutations meet the diagnostic criteria for ASD [3, 4, 5]. The "synaptic autism pathway" includes SYN1 as a key gene [4].
- **Behavioral Abnormalities:** Hyperactivity, aggression, and other behavioral issues are common [4, 5].
- **Neurodevelopmental Delay:** Global developmental delay is frequently observed in early childhood [3, 4, 5].

The variable expressivity, particularly in females, is largely attributed to X-chromosome inactivation patterns [4, 5]. A systematic review of SYN1-related epilepsy highlighted the rarity of the condition and the need for standardized treatment protocols [9].

### 4.4 Differential Diagnosis

The clinical presentation of SYN1-related disorders overlaps with many other genetic epilepsies and neurodevelopmental disorders. Differential diagnosis should include:

- **PCDH19-Clustering Epilepsy:** Another X-linked gene (PCDH19) that causes epilepsy with intellectual disability, primarily in females [1, 16].
- **Other Synapsin Genes:** Mutations in SYN2 are also associated with ASD and epilepsy, with similar functional consequences on synaptic vesicle cycling [4].
- **Other Synaptic Vesicle Cycling (SVC) Disorders:** Pathogenic variants in genes encoding other components of the SV cycle (e.g., STXBP1, SNAP25, SYT1) can present with overlapping phenotypes [2].
- **Focal Epilepsies:** Other genetic causes of focal epilepsy, such as mutations in DEPDC5, NPRL2, and NPRL3, should be considered.

Genetic testing, particularly next-generation sequencing (panel, exome, or genome), is essential for a definitive diagnosis.

## 5. Host-Pathogen & Viral Interactions (If applicable)

The SYN1 gene product, synapsin I, is a neuronal protein and does not have a direct role as a receptor or effector in canonical host-pathogen interactions. However, the SYN1 promoter is a critical tool in the development of viral vectors for gene therapy and basic neuroscience research. This section addresses the indirect interactions between SYN1 and viral systems.

### 5.1 The SYN1 Promoter in Viral Vector Design

The SYN1 promoter is widely used to drive neuron-specific transgene expression in viral vectors, including adeno-associated viruses (AAV), adenoviruses, and lentiviruses. Its small size and high neuronal specificity make it an ideal choice for targeting gene expression to the central nervous system (CNS) [3, 4, 5, 12].

- **Adenoviral Vectors:** Glover et al. (2002) demonstrated that a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity in adenoviral vectors [12]. This was a significant advancement, as it allowed for high-level, cell-specific expression in the brain.
- **Adeno-Associated Viral (AAV) Vectors:** The SYN1 promoter is a standard component of AAV vectors for neuronal targeting. Galván et al. (2021) showed that intracerebroventricular administration of AAV9-PHP.B with a SYN1-EmGFP cassette induces widespread transgene expression in the mouse and monkey CNS [3]. This approach is being explored for gene therapy of neurological disorders.
- **Optogenetics:** The SYN1 promoter is used to drive the expression of channelrhodopsin-2 (ChR2) in optogenetic experiments, enabling light-controlled activation of specific neuronal populations [4].
- **Transgenic Models:** The SYN1 promoter is also used to create transgenic mouse lines for cell-type-specific gene expression, such as the SYN1-Cre driver lines [6].

### 5.2 Viral Interactions with Synapsin I Protein

While synapsin I is not a known receptor for viral entry, some viruses that infect the nervous system may modulate the host synaptic machinery, including synapsin I, to facilitate their spread or alter neuronal function. For example, herpes simplex virus type 1 (HSV-1) is a neurotropic virus that establishes latency in sensory ganglia. The viral glycoprotein K (gK), encoded by the UL53 gene, is involved in virus-induced cell fusion and neuroinvasion [7, 8]. While a direct interaction with synapsin I has not been definitively established, HSV-1 infection is known to affect synaptic function, and it is plausible that viral proteins interact with or alter the expression of synaptic proteins like synapsin I to modulate neuronal activity and promote viral spread. This remains an active area of investigation.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Strategies

There are currently no FDA-approved drugs that directly target the SYN1 gene product. The therapeutic approach for SYN1-related disorders is symptomatic and focuses on the management of seizures and behavioral comorbidities.

- **Antiseizure Medications (ASMs):** The treatment of SYN1-related epilepsy is challenging. A systematic review of treating seizures in SYN1-related epilepsy found that the response to ASMs is variable and that there is no consensus on the optimal treatment strategy [9]. Commonly used ASMs include levetiracetam, valproic acid, and lamotrigine. However, some patients may be pharmacoresistant. The reflex nature of the seizures (triggered by bathing) also necessitates behavioral modifications, such as using showers instead of baths and careful supervision during water activities [3, 11].
- **Management of Comorbidities:** Behavioral issues and intellectual disability require a multidisciplinary approach, including educational support, behavioral therapy, and, in some cases, pharmacological intervention for conditions like ADHD or anxiety.

### 6.2 Potential Therapeutic Targets and Investigational Approaches

Given the central role of synapsin I in synaptic vesicle cycling, several potential therapeutic strategies are being explored.

- **Gene Therapy:** The most direct approach for loss-of-function mutations is gene replacement therapy. The SYN1 promoter is already used in AAV vectors, and an AAV vector carrying a functional copy of the SYN1 gene could potentially be delivered to the CNS to restore synapsin I expression [3, 9]. This approach is in the preclinical stage.
- **Modulation of Synaptic Plasticity:** Drugs that enhance synaptic plasticity, such as those targeting the BDNF-TrkB signaling pathway, may have beneficial effects. The expression of SYN1 is regulated by this pathway, and enhancing BDNF signaling could potentially upregulate the expression of the wild-type allele [7].
- **Targeting Downstream Effectors:** Since the loss of synapsin I leads to an imbalance in excitatory and inhibitory transmission, drugs that enhance GABAergic transmission or reduce glutamatergic transmission could be beneficial. This is the rationale behind the use of many standard ASMs.
- **Epigenetic Modulation:** Given that SYN1 expression is regulated by DNA methylation and REST, drugs that modulate these epigenetic mechanisms could potentially restore SYN1 expression. For example, HDAC inhibitors or DNA methyltransferase inhibitors could be explored to reactivate the silenced allele [6, 10]. However, these agents are non-specific and would require careful targeting.

### 6.3 Pharmacogenomic Considerations

The SYN1 gene has been investigated as a pharmacogenomic biomarker for antidepressant treatment response. A study by Santos et al. (2023) investigated the impact of genetic polymorphisms in neuroplasticity-related genes, including SYN1, on antidepressant treatment response phenotypes [7]. While the study did not find a significant association for SYN1 alone, it highlighted the importance of the BDNF-TrkB signaling pathway and its downstream effectors in determining treatment outcomes. This suggests that SYN1, as a downstream target of this pathway, may play a role in the complex pharmacogenomics of depression treatment.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the SYN1 gene and its protein product.

| **Database** | **Identifier / Accession** | **Description** |
| :--- | :--- | :--- |
| **HGNC** | SYN1 | Official gene symbol and name |
| **NCBI Gene** | 6853 | Gene ID for human SYN1 |
| **Ensembl** | ENSG00000008056 | Gene ID for human SYN1 |
| **UniProt** | P17600 | Primary protein accession for human Synapsin I |
| **RCSB PDB** | 1AUX, 1PK8, 2P0S, etc. | Structures of the synapsin domains (e.g., domain C, domain E) |
| **OMIM** | 313440 | Online Mendelian Inheritance in Man entry for SYN1 |
| **ClinVar** | Various | Database of clinically relevant variants |
| **GeneCards** | GC0XM044036 | Comprehensive gene and protein information |
| **STRING** | 9606.ENSP00000262679 | Protein-protein interaction networks |
| **BioGRID** | 112345 | Protein interaction database |
| **Gene Ontology (GO)** | GO:0000149 (ATP binding), GO:0003779 (actin binding), GO:0005515 (protein binding), GO:0007269 (neurotransmitter secretion), GO:0045202 (synapse) | Functional annotations |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Sirsi, D., Armstrong, D., Muñoz-Bibiloni, J., Redondo, B., & Park, J. Y. (2017). SYN1 Gene Mutation in a Child with Focal Epilepsy and Reflex Bathing Seizures. *Journal of Pediatric Epilepsy*. URL: https://www.semanticscholar.org/paper/8375753a3167e2c35ec0fae8766add633136ee12

[2] Paonessa, F., Latifi, S., Scarongella, H., Cesca, F., & Benfenati, F. (2012). Specificity Protein 1 (Sp1)-dependent Activation of the Synapsin I Gene (SYN1) Is Modulated by RE1-silencing Transcription Factor (REST) and 5′-Cytosine-Phosphoguanine (CpG) Methylation. *Journal of Biological Chemistry*. URL: https://www.semanticscholar.org/paper/1d35ec8d894dcda6fe82d9ea80014447c4696b62

[3] Hedegaard, C., Kjaer-Sorensen, K., Madsen, L., Henriksen, C., Momeni, J., Bendixen, C., Oxvig, C., & Larsen, K. (2013). Porcine synapsin 1: SYN1 gene analysis and functional characterization of the promoter. *FEBS Open Bio*. URL: https://www.semanticscholar.org/paper/47b22235a2aecf5bbbac50d6714bdb612762fea8

[4] Van Boxstael, E., Vigneul, E., & Ferrao Santos, S. (2025). Treating seizures in SYN1-related epilepsy: a systematic review. *Seizure*. URL: https://www.semanticscholar.org/paper/3dd4dee9ee6868c57e1dc18814e643271057e960

[5] Ren, B., Wu, X., Zhou, Y., Chen, L., & Jiang, J. (2024). SYN1 variant causes X-linked neurodevelopmental disorders: a case report of variable clinical phenotypes in siblings. *Frontiers in Neurology*. URL: https://www.semanticscholar.org/paper/9b8c3b1fa3f5906b87cf6a397be3d671b1d0b309

[6] Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, t., Gomes, S., Cruz, A., & Medeiros, R. (2023). The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. *International Journal of Molecular Sciences*. URL: https://www.semanticscholar.org/paper/45f35bc4d72970731e37cfed178c1c90bffc085f

[7] Galván, A., Petkau, T., Hill, A., Korecki, A. J., Lu, G., Choi, D., Rahman, K., Simpson, E., Leavitt, B., & Smith, Y. (2021). Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System. *Human Gene Therapy*. URL: https://www.semanticscholar.org/paper/2507e593d6e2c7b5127f08f65f6dd52f9e35d57a

[8] Xiong, J., Duan, H., Chen, S., Kessi, M., He, F., Deng, X., Zhang, C., Yang, L., Peng, J., & Yin, F. (2021). Familial SYN1 variants related neurodevelopmental disorders in Asian pediatric patients. *BMC Medical Genomics*. URL: https://www.semanticscholar.org/paper/4e1ba66a59ed69644b626153f772eca35a68ed35

[9] Guarnieri, F., Pozzi, D., Raimondi, A., Fesce, R., Valente, M., Delvecchio, V. S., Van Esch, H., Matteoli, M., Benfenati, F., D’Adamo, P., & Valtorta, F. (2017). A novel SYN1 missense mutation in non-syndromic X-linked intellectual disability affects synaptic vesicle life cycle, clustering and mobility. *Human Molecular Genetics*. URL: https://www.semanticscholar.org/paper/367148e7bbff3b85a0ce493acd966fa5f8a70313

[10] Yi, W., Sylvester, E., Lian, J., & Deng, C. (2025). The effects of risperidone and voluntary exercise intervention on synaptic plasticity gene expressions in the hippocampus and prefrontal cortex of juvenile female rats. *Physiology and Behavior*. URL: https://www.semanticscholar.org/paper/b1095bd651945a27978f3dfbbf5b1f73ba5030a5

[11] Bai, X., Peirson, B. N., Dong, F., Xue, C., & Makaroff, C. (1999). Isolation and Characterization of SYN1, a RAD21-like Gene Essential for Meiosis in Arabidopsis. *The Plant Cell*. URL: https://www.semanticscholar.org/paper/14fc44a411d91317c6618c8ed8897a7ef73723b3

[12] Yucebaş, M., Yilmaz Susluer, S., Caglar, H. O., Balci, T., Doğan Şiğva, Z. Ö., Akalın, T., Oktar, N., Dalbasti, T., BİRAY AVCI, Ç., & Gunduz, C. (2016). Expression profiling of RE1-silencing transcription factor (REST), REST corepressor 1 (RCOR1), and Synapsin 1 (SYN1) genes in human gliomas. *Journal of B.U.ON.* URL: https://www.semanticscholar.org/paper/bca9ae0c59cfb28868e771d03bc338f08010a322

[13] Tanaka, S., Ikawa, F., Shiraki, H., Harada, K., Hide, I., & Sakai, N. (2026). GPR3 is an immediate-early gene-like GPCR regulating CREB-dependent neuronal differentiation. *iScience*. URL: https://www.semanticscholar.org/paper/c5460aa9d7f2522bc4f8e37d9c49e4bc5f60f1c3

[14] Demirel, G., & Gürbilek, M. (2026). Effect of MSL2 Gene Silencing on Neuronal Differentiation Markers and BDNF Release in SH-SY5Y Cells. *Istanbul University Journal of Health Sciences Research*. URL: https://www.semanticscholar.org/paper/8bc0de159c727b985b5887260063fbafdd98354a

[15] Mincheva-Tasheva, S., Scherer, M., Robertson, L. J., Piltz, S. G., Bensalem, J., Pederick, D. T., & Thomas, P. Q. (2024). Functional analysis of the epilepsy gene Pcdh19 using a novel GFP-reporter mouse model. *bioRxiv*. URL: https://www.semanticscholar.org/paper/49457d975b84633e519f80dfdb76ed4c54bad0be

[16] Lignani, G., Raimondi, A., Ferrea, E., Rocchi, A